TLPLDC vaccine + checkpoint inhibitor

**TLPLDC vaccine + checkpoint inhibitor** refers to a combination therapy for cancer, specifically advanced or high-risk melanoma. The TLPLDC vaccine is an autologous therapeutic cancer vaccine developed from a patient’s own tumor lysate, loaded into yeast cell wall particles, and introduced to their dendritic cells. This vaccine is designed to stimulate both innate and adaptive immune responses, activating T cells to recognize and destroy tumor cells. It is used in conjunction with standard-of-care immune checkpoint inhibitors (such as PD-1, PD-L1, or CTLA-4 blocking antibodies), which release inhibitory signals on T cells and enhance anti-tumor immunity. The combination aims to provide synergistic anti-tumor effects: checkpoint inhibitors augment T-cell responses induced by the vaccine, potentially improving outcomes in patients who do not fully respond to checkpoint inhibitor monotherapy. Phase IIb and ongoing phase III trials target metastatic and resected stage III/IV melanoma, with Elios Therapeutics as the main developer[2][5][6][1][3][4].

Other names

tumor lysate, particle-loaded, dendritic cell vaccine + checkpoint inhibitor